Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Neoplasm Metastasis 36Leukemia, Myeloid, Acute 32Multiple Myeloma 27Lymphoma 23Breast Neoplasms 18Prostatic Neoplasms 17Pancreatic Neoplasms 17Colorectal Neoplasms 17Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 15Myelodysplastic Syndromes 14Leukemia, Lymphocytic, Chronic, B-Cell 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Lung Neoplasms 11Sarcoma 10Lymphoma, T-Cell 9Glioma 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Leukemia, Biphenotypic, Acute 7Endometrial Neoplasms 7

Interventions

Specimen Handling 6Interviews as Topic 4Standard of Care 3Practice Guidelines as Topic 3Biopsy 3X-Rays 2Methods 2Educational Status 2Early Intervention, Educational 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Verteporfin 1Trastuzumab 1Palliative Care 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Iohexol 1Health Promotion 1Exercise Test 1Carboplatin 1CT-P6 1Asian ginseng 1Art Therapy 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Malignant Solid Neoplasm × Biopsy × 90 days × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06351371 2026-05-28

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡